Show simple item record

Files in this item


Item metadata

dc.contributor.authorPhillips, K-A
dc.contributor.authorCollins, I M
dc.contributor.authorMilne, R L
dc.contributor.authorMcLachlan, S A
dc.contributor.authorFriedlander, M
dc.contributor.authorHickey, M
dc.contributor.authorStern, C
dc.contributor.authorHopper, J L
dc.contributor.authorFisher, R
dc.contributor.authorKannemeyer, G
dc.contributor.authorPicken, S
dc.contributor.authorSmith, C D
dc.contributor.authorKelsey, Thomas William
dc.contributor.authorAnderson, R A
dc.identifier.citationPhillips , K-A , Collins , I M , Milne , R L , McLachlan , S A , Friedlander , M , Hickey , M , Stern , C , Hopper , J L , Fisher , R , Kannemeyer , G , Picken , S , Smith , C D , Kelsey , T W & Anderson , R A 2016 , ' Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations ' , Human Reproduction , vol. 31 , no. 5 , pp. 1126-1132 . ,
dc.identifier.otherPURE: 239828466
dc.identifier.otherPURE UUID: 238a8198-5715-4bd6-82b5-820eac3a1189
dc.identifier.otherPubMed: 27094481
dc.identifier.otherScopus: 84966339522
dc.identifier.otherPubMed: 27094481
dc.identifier.otherPubMedCentral: PMC4840025
dc.identifier.otherORCID: /0000-0002-8091-1458/work/27201529
dc.identifier.otherWOS: 000376402300023
dc.descriptionStudy funding/competing interest(s): kConFab is supported by a grant from the Australian National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. KAP is an Australian National Breast Cancer Foundation Practitioner Fellow. JLH is a NHMRC Senior Principal Research Fellow. MH is a NHMRC Practitioner Fellow. RA reports personal fees from Roche Diagnostics & Beckman Coulter outside the submitted work and CS reports other from Melbourne IVF outside the submitted work. The remaining authors have nothing to declare and no conflicts of interest.en
dc.description.abstractStudy question: Do women with BRCA1 and BRCA2 mutations have reduced ovarian reserve, as measured by circulating anti-müllerian hormone (AMH) concentration?  Summary answer: Women with a germline mutation in BRCA1 have reduced ovarian reserve as measured by AMH.  What is known already: The DNA repair enzymes encoded by BRCA1 and BRCA2 are implicated in reproductive aging. Circulating AMH is a biomarker of ovarian reserve and hence reproductive lifespan.  Study design, size, duration: Cross-sectional study of AMH concentrations of 693 women at the time of enrolment into the Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer (kConFab) cohort study (recruitment from 19/08/1997 until 18/9/2012). AMH was measured on stored plasma samples between November 2014 and January 2015 using an electrochemiluminescence immunoassay platform.  Participants/materials, setting, methods: Eligible women were from families segregating BRCA1 or BRCA2 mutations and had known mutation status. Participants were aged 25 to 45 years, had no personal history of cancer, retained both ovaries and were not pregnant or breastfeeding at the time of plasma storage. Circulating AMH was measured for 172 carriers and 216 non-carriers from families carrying BRCA1 mutations, and 147 carriers and 158 non-carriers from families carrying BRCA2 mutations. Associations between plasma AMH concentration and carrier status were tested by linear regression, adjusted for age at plasma storage, oral contraceptive use, body mass index and cigarette smoking.  Main results and the role of chance: Mean AMH concentration was negatively associated with age (P < 0.001). Mutation carriers were younger at blood draw than non-carriers (P ≤ 0.031). BRCA1 mutation carriers had, on average, 25% (95% CI: 5% - 41%, P = 0.02) lower AMH concentrations than non-carriers and were more likely to have AMH concentrations in the lowest quartile for age (OR 1.84, 95% CI: 1.11-303, P=0.02). There was no evidence of an association between AMH concentration and BRCA2 mutation status (P = 0.94).  Limitations, reasons for caution: The clinical implications of the lower AMH concentrations seen in BRCA1 mutation carriers cannot be assessed by this study design.  Wider implications of the findings: Women with a germline mutation in BRCA1 may have reduced ovarian reserve. This is consistent with other smaller studies in the literature and has potential implications for fertility and reproductive lifespan. 
dc.relation.ispartofHuman Reproductionen
dc.rightsCopyright © The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comen
dc.subjectAnit-Müllerian hormoneen
dc.subjectOvarian reserveen
dc.subjectDNA repairen
dc.subjectRG Gynecology and obstetricsen
dc.subjectQA75 Electronic computers. Computer scienceen
dc.subjectQH426 Geneticsen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleAnti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutationsen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Computer Scienceen
dc.contributor.institutionUniversity of St Andrews. Centre for Interdisciplinary Research in Computational Algebraen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record